117 related articles for article (PubMed ID: 29674509)
1. Antigen Presentation Keeps Trending in Immunotherapy Resistance.
Kalbasi A; Ribas A
Clin Cancer Res; 2018 Jul; 24(14):3239-3241. PubMed ID: 29674509
[TBL] [Abstract][Full Text] [Related]
2. The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression.
Huang L; Malu S; McKenzie JA; Andrews MC; Talukder AH; Tieu T; Karpinets T; Haymaker C; Forget MA; Williams LJ; Wang Z; Mbofung RM; Wang ZQ; Davis RE; Lo RS; Wargo JA; Davies MA; Bernatchez C; Heffernan T; Amaria RN; Korkut A; Peng W; Roszik J; Lizée G; Woodman SE; Hwu P
Clin Cancer Res; 2018 Jul; 24(14):3366-3376. PubMed ID: 29496759
[No Abstract] [Full Text] [Related]
3. Allele-specific peptide presentation of human leukocyte antigens: implications for tumor immunotherapy.
Elsner HA; Eiz-Vesper B; Blasczyk R; Bade-Döding C
Anticancer Res; 2007; 27(4A):2075-7. PubMed ID: 17649824
[TBL] [Abstract][Full Text] [Related]
4. Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer.
Liu H; Xu Y; Xiang J; Long L; Green S; Yang Z; Zimdahl B; Lu J; Cheng N; Horan LH; Liu B; Yan S; Wang P; Diaz J; Jin L; Nakano Y; Morales JF; Zhang P; Liu LX; Staley BK; Priceman SJ; Brown CE; Forman SJ; Chan VW; Liu C
Clin Cancer Res; 2017 Jan; 23(2):478-488. PubMed ID: 27535982
[TBL] [Abstract][Full Text] [Related]
5. Neoantigen: A Long March toward Cancer Immunotherapy.
Liu Y
Clin Cancer Res; 2016 Jun; 22(11):2602-4. PubMed ID: 27006495
[TBL] [Abstract][Full Text] [Related]
6. Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma.
Komohara Y; Harada M; Arima Y; Suekane S; Noguchi M; Yamada A; Itoh K; Matsuoka K
Int J Oncol; 2006 Dec; 29(6):1555-60. PubMed ID: 17088996
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapy targeting survivin: commentary re: V. Pisarev et al., full-length dominant-negative survivin for cancer immunotherapy. Clin. Cancer Res., 9:6523-6533, 2003.
Reed JC; Wilson DB
Clin Cancer Res; 2003 Dec; 9(17):6310-5. PubMed ID: 14695129
[No Abstract] [Full Text] [Related]
8. Antigen Presentation by Individually Transferred HLA Class I Genes in HLA-A, HLA-B, HLA-C Null Human Cell Line Generated Using the Multiplex CRISPR-Cas9 System.
Hong CH; Sohn HJ; Lee HJ; Cho HI; Kim TG
J Immunother; 2017; 40(6):201-210. PubMed ID: 28604557
[TBL] [Abstract][Full Text] [Related]
9. HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy.
Fauquembergue E; Toutirais O; Tougeron D; Drouet A; Le Gallo M; Desille M; Cabillic F; de La Pintière CT; Iero M; Rivoltini L; Baert-Desurmont S; Leprince J; Vaudry H; Sesboué R; Frébourg T; Latouche JB; Catros V
J Immunother; 2010 May; 33(4):402-13. PubMed ID: 20386466
[TBL] [Abstract][Full Text] [Related]
10. Identification of the HLA-Cw*0702-restricted tumor-associated antigen recognized by a CTL clone from a lung cancer patient.
Nagata Y; Hanagiri T; Takenoyama M; Fukuyama T; Mizukami M; So T; Ichiki Y; Sugaya M; Sugio K; Yasumoto K
Clin Cancer Res; 2005 Jul; 11(14):5265-72. PubMed ID: 16033845
[TBL] [Abstract][Full Text] [Related]
11. Genetic variation in antigen presentation and cancer immunotherapy.
Sivapalan L; Anagnostou V
Immunity; 2022 Jan; 55(1):3-6. PubMed ID: 35021056
[TBL] [Abstract][Full Text] [Related]
12. Ring finger protein 43 as a new target for cancer immunotherapy.
Uchida N; Tsunoda T; Wada S; Furukawa Y; Nakamura Y; Tahara H
Clin Cancer Res; 2004 Dec; 10(24):8577-86. PubMed ID: 15623641
[TBL] [Abstract][Full Text] [Related]
13. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination.
Kather A; Ferrara A; Nonn M; Schinz M; Nieland J; Schneider A; Dürst M; Kaufmann AM
Int J Cancer; 2003 Apr; 104(3):345-53. PubMed ID: 12569558
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of Myelodysplastic Syndrome: You Can Run, but You Can't Hide.
Fuchs EJ
Clin Cancer Res; 2018 Mar; 24(5):991-993. PubMed ID: 29284705
[TBL] [Abstract][Full Text] [Related]
15. SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4
Lacher MD; Bauer G; Fury B; Graeve S; Fledderman EL; Petrie TD; Coleal-Bergum DP; Hackett T; Perotti NH; Kong YY; Kwok WW; Wagner JP; Wiseman CL; Williams WV
Front Immunol; 2018; 9():776. PubMed ID: 29867922
[TBL] [Abstract][Full Text] [Related]
16. Revisiting Interleukin-12 as a Cancer Immunotherapy Agent.
Berraondo P; Etxeberria I; Ponz-Sarvise M; Melero I
Clin Cancer Res; 2018 Jun; 24(12):2716-2718. PubMed ID: 29549160
[TBL] [Abstract][Full Text] [Related]
17. CART Targeting of Solid Tumors: More Pieces to the Puzzle.
Kalos M
Clin Cancer Res; 2018 Mar; 24(6):1246-1247. PubMed ID: 29348296
[TBL] [Abstract][Full Text] [Related]
18. Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.
Lemmermann NA; Reddehase MJ
Med Microbiol Immunol; 2016 Dec; 205(6):549-561. PubMed ID: 27539576
[TBL] [Abstract][Full Text] [Related]
19. Identification of HLA a*0201 glioblastoma multiforme cell lines for immunotherapy by PCR-SSP and DNA sequencing.
Wu AH; Hall WA; Low WC
J Neurooncol; 2004 Jan; 66(1-2):1-8. PubMed ID: 15015764
[TBL] [Abstract][Full Text] [Related]
20. Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses.
Hirano N; Butler MO; Xia Z; Berezovskaya A; Murray AP; Ansén S; Nadler LM
Clin Cancer Res; 2006 May; 12(10):2967-75. PubMed ID: 16707591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
